Literature DB >> 7543077

The prognostic influence of neuroendocrine cells in prostate cancer: results of a long-term follow-up study with patients treated by radical prostatectomy.

M A Noordzij1, T H van der Kwast, G J van Steenbrugge, W J Hop, F H Schröder.   

Abstract

The distribution of immunohistochemically defined neuroendocrine (NE) cells in benign, pre-cancerous and neoplastic prostatic tissues and the prognostic value of these cells in prostate cancer were studied in the radical prostatectomy specimens of 90 patients from whom complete long-term follow-up data were available. The tissue blocks containing all the different Gleason patterns observed in a particular tumor were selected and immunostained. Since chromogranin B stained only a few cells compared to chromogranin A (CgA), NE cells were only defined by their reactivity with CgA. A semi-quantificative CgA score was assessed for all distinct pathological areas. Cox's regression model was used to analyze the influence of final TNM classification (TNM, 1992), Gleason sum score (GSS), age and CgA score on the probability of progression and tumor-specific death. NE cells were demonstrated in all normal prostatic tissues and in most hyperplastic and intra-epithelial neoplastic lesions. CgA staining was seen in 78% of the tumors. CgA scores were not related with Gleason growth patterns, GSS or TNM classification and had no prognostic value. The independent prognostic variables in Cox's regression model were: GSS and pT stage for progression and GSS for tumor-specific survival. Theoretically, NE cells could influence tumor behavior and this discrepancy suggests the need for experimental studies to investigate the role of NE cells in the normal and neoplastic prostate.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7543077     DOI: 10.1002/ijc.2910620304

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  11 in total

1.  [Relevance of the neuroendocrine differentiation in prostatic carcinoma].

Authors:  C G Sauer; L Trojan; R Grobholz
Journal:  Pathologe       Date:  2005-11       Impact factor: 1.011

2.  Kinetics of neuroendocrine differentiation in an androgen-dependent human prostate xenograft model.

Authors:  J Jongsma; M H Oomen; M A Noordzij; W M Van Weerden; G J Martens; T H van der Kwast; F H Schröder; G J van Steenbrugge
Journal:  Am J Pathol       Date:  1999-02       Impact factor: 4.307

Review 3.  Neuroendocrine differentiation of prostate cancer: a review.

Authors:  Vamsi Parimi; Rajen Goyal; Kate Poropatich; Ximing J Yang
Journal:  Am J Clin Exp Urol       Date:  2014-12-09

Review 4.  Imaging of neuroendocrine neoplasms of the male GU tract.

Authors:  Kedar G Sharbidre; Ajaykumar C Morani; Mohd Zahid; Priya Bhosale; Chandana Lall; Isaac R Francis; Sadhna Verma
Journal:  Abdom Radiol (NY)       Date:  2022-04-12

5.  Neuroendocrine differentiation in the setting of prostatic carcinoma: contemporary assessment of a consecutive series.

Authors:  Anuradha Gopalan; Hikmat Al-Ahmadie; Ying-Bei Chen; Judy Sarungbam; S Joseph Sirintrapun; Satish K Tickoo; Victor E Reuter; Samson W Fine
Journal:  Histopathology       Date:  2022-07-11       Impact factor: 7.778

6.  Incidence of neuroendocrine cells in the seminal vesicles and the prostate--an immunohistochemical study.

Authors:  Hans Jörg Sommerfeld; Alan Wayne Partin; Jürgen Pannek
Journal:  Int Urol Nephrol       Date:  2002       Impact factor: 2.370

7.  Neuroendocrine differentiation in human prostatic tumor models.

Authors:  M A Noordzij; W M van Weerden; C M de Ridder; T H van der Kwast; F H Schröder; G J van Steenbrugge
Journal:  Am J Pathol       Date:  1996-09       Impact factor: 4.307

Review 8.  Neuroendocrine Tumors of the Prostate: Emerging Insights from Molecular Data and Updates to the 2016 World Health Organization Classification.

Authors:  David S Priemer; Rodolfo Montironi; Lisha Wang; Sean R Williamson; Antonio Lopez-Beltran; Liang Cheng
Journal:  Endocr Pathol       Date:  2016-06       Impact factor: 3.943

9.  Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance.

Authors:  Harsimar Kaur; Iryna Samarska; Jiayun Lu; Farzana Faisal; Benjamin L Maughan; Sanjana Murali; Kaushal Asrani; Mohamed Alshalalfa; Emmanuel S Antonarakis; Jonathan I Epstein; Corinne E Joshu; Edward M Schaeffer; Juan Miguel Mosquera; Tamara L Lotan
Journal:  Prostate       Date:  2020-07-10       Impact factor: 4.012

10.  Correlation of three immunohistochemically detected markers of neuroendocrine differentiation with clinical predictors of disease progression in prostate cancer.

Authors:  M Hammad Ather; Farhat Abbas; Nuzhat Faruqui; Mohammad Israr; Shahid Pervez
Journal:  BMC Urol       Date:  2008-12-30       Impact factor: 2.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.